Ann: First Patients Recruited into BTX 1503 Phase 2 Acne Trial, page-112

Originally posted by beefarmer
One thing that comforts me is the 'whole kit and kabbodle' approach by potential big pharma looking at us in the future.
Maybe at present as alluded.
Of course it gets down to the results but there has been another $630 million tossed down the gurgler by Johnson and Johnson after a phase 2b drug didn't excite. Compare that to the simplicity and hopefully efficacy of acne, dermatitis, psoriasis and God only knows what.
Now think of a $250 million dollar deal with royalties on top and you see where we could be going. Pie in the sky? Who knows. Pink Floyd had a pig in the sky and that worked. The whole kit and kaboodle. Damn tempting to own the rights to the first commercial CBD FDA approved derma company.

That's what we are all here for isn't it folks? Bags and bags.​

I ‘m comforted also by the fact ( which seems to be overlooked ) that BOT’s compounds are been endorsed by individuals with a lot of professional “capital”, one accumulated over a lifetime of work. Why would someone with hard earned credentials be associated with a less than outstanding product? I’m not just referring to the scientists from QU for the study of the antibiotic properties of BTX1801 or to the new CMO - Dr Levy . Take Prof Sinclair for example: he has agreed to appear on both Channel 9 and 7 news ( as he was part of BTX1503 phase1 as we’ll as the current phase2 ), his credentials are quite remarkable: Professor Rodney Sinclair is Professor of Dermatology at the University of Melbourne and Director of Epworth Dermatology. He is past-president of the Australasian Society for Dermatology Research, the Australasian Hair and Wool Research Society and the Skin and Cancer Foundation of Victoria.Prof Sinclair is the co-author of the section on dermatology in the Oxford Textbook of Medicine and lead author of Therapeutic Guidelines – Dermatology. He has written 13 textbooks on dermatology, and has over 400 research publications to his name.Prof Sinclair convened the World Congress of Cosmetic Dermatology in Melbourne in 2006 and the World Congress of Hair Research in Cairns in 2010. Why would someone like Prof Sinclair agree to comment on the efficacy of BTX1503 on public television if he wasn’t himself convinced that the compound has outstanding properties? Only anedoctal? I don’t think so, you’re right Beefarmer: I am in for bags and bags.